Meet the Proteona team at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will be at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco from the 13th to the 16th January, 2020.
The annual event is the largest symposium for healthcare investment, attracting industry players, startups, and investors. We are excited to be there to discuss the impact of single cell multi-omics on the future of precision medicine. See you there!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.